Edition:
United States

Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

98.64USD
4:01pm EDT
Change (% chg)

$-0.06 (-0.06%)
Prev Close
$98.70
Open
$98.30
Day's High
$98.82
Day's Low
$97.50
Volume
182,350
Avg. Vol
289,509
52-wk High
$100.00
52-wk Low
$69.65

Latest Key Developments (Source: Significant Developments)

Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017
Monday, 13 Mar 2017 04:40pm EDT 

Vermillion Inc : Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017 .Vermillion Inc - primary purpose of amendment was to extend initial term of testing and services agreement from March 11, 2017 to March 11, 2018.  Full Article

Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis
Wednesday, 8 Feb 2017 08:00am EST 

Veracyte Inc : Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics . Says quest diagnostics is expected to begin offering test to its customers nationally in Q2 of 2017 . Says financial and other terms of agreement were not disclosed. .Physician clients of quest diagnostics will be able to order test on behalf of patients, refer patient specimens to co for genomic testing.  Full Article

Quest Diagnostics posts Q4 diluted EPS of $1.09 per share
Thursday, 26 Jan 2017 06:45am EST 

Quest Diagnostics Inc: Reports Q4 adjusted earnings per share $1.31 excluding items . Reports FY 2016 adjusted earnings per share $5.15 . Reports Q4 2016 revenue $1.86 billion . Reports Q4 2016 revenue up 0.7 percent . Quest diagnostics reports fourth quarter and full year 2016 financial results; provides guidance for full year 2017 . Q4 revenues of $1.86 billion, up 0.7% on a reported basis and up 1.9% on an equivalent basis versus 2015 . Quest diagnostics inc says full year 2017 reported diluted eps expected to be between $4.65 and $4.80 . Q4 diluted EPS of $1.09 on a reported basis . Fy2017 earnings per share view $5.45 -- Thomson Reuters I/B/E/S . Q4 diluted eps of $1.31 on an adjusted basis . Quest diagnostics Inc sees fy 2017 capital expenditures btwn $250 million- $300 million . Quest Diagnostics Inc sees fy 2017 revenues $7.64 billion- $7.72 billion . Fy2017 revenue view $7.66 billion -- Thomson Reuters I/B/E/S .Quest diagnostics inc sees fy 2017 diluted eps $4.65- $4.80.  Full Article

Quest Diagnostics launches hepatitis b virus quantitative test
Wednesday, 18 Jan 2017 08:00am EST 

Quest Diagnostics Inc :Launches hepatitis b virus quantitative test to help assess response to antiviral therapy.  Full Article

Oxford Immunotec announces favorable recommendation by the magistrate judge
Thursday, 1 Sep 2016 07:03am EDT 

Oxford Immunotec Global PLC : Oxford Immunotec announces favorable recommendation by the magistrate judge in patent infringement litigation . Says recommendation denying in substantial part defendants' motion to dismiss company's claims . Patent infringement lawsuit against Qiagen Inc, Quest Diagnostics Inc and Laboratory Corporation of America Holdings .Says recommendation should now "allow company to press forward with its case against three defendants".  Full Article

Quest Diagnostics approved to use electronic drug test process for federally-mandated workforce by U.S. Health and Human Services
Thursday, 18 Aug 2016 10:53am EDT 

Quest Diagnostics : Quest Diagnostics approved to use electronic drug test process for federally-mandated workforce by U.S. Health and Human Services .Plans to make federal ECCF broadly available to its clients in Q4..  Full Article

Quest Diagnostics, AncestryDNA collaborate on consumer DNA testing
Wednesday, 3 Aug 2016 06:45am EDT 

Quest Diagnostics Inc :Co and ancestrydna collaborate to expand consumer dna testing; additional terms of deal were not disclosed.  Full Article

Quest Diagnostics Q2 earnings $1.37/ share
Thursday, 21 Jul 2016 06:45am EDT 

Quest Diagnostics Inc : Quest diagnostics reports second quarter 2016 financial results . Q2 earnings per share $1.37 . Q2 adjusted earnings per share $1.34 . Q2 earnings per share view $1.32 -- Thomson Reuters I/B/E/S . Q2 revenue $1.91 billion versus i/b/e/s view $1.91 billion . Updates full-year reported EPS guidance and maintains full year adjusted outlook . Sees full-year 2016 adjusted earnings per share $5.02 to $5.17 excluding items . Sees full-year 2016 earnings per share $4.18 to $4.33 . Full-year 2016 earnings per share view $5.10 -- Thomson Reuters I/B/E/S . Sees full-year 2016 revenue $7.47 billion to $7.54 billion . Full-year 2016 revenue view $7.53 billion -- Thomson Reuters I/B/E/S .Full-year 2016 capital expenditures to be between $250 million and $300 million.  Full Article

Quest diagnostics quest to relocate headquarters to 500 plaza drive in Secaucus, NJ
Monday, 20 Jun 2016 05:00am EDT 

Quest Diagnostics Inc :Quest diagnostics to relocate headquarters to 500 plaza drive in Secaucus, NJ.  Full Article

Quest Diagnostics entered into an accelerated share repurchase agreement to repurchase about $250 mln common stock
Friday, 20 May 2016 04:36pm EDT 

Quest Diagnostics Inc : Entered into an accelerated share repurchase agreement to repurchase approximately $250 million of company's common stock . Under asr agreement, company made a $250 million payment to morgan stanley & co on may 20, 2016 .Transaction is expected to be completed during q3 of 2016.  Full Article

More From Around the Web

BRIEF-Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017

* Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017